Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s ...

Roche Holdings AG RHHBY is a major shareholder of Chugai, a Japanese pharmaceutical company ... Also Read: Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market ...

Also Read: Eli Lilly’s Obesity Drug Success Spurs Japanese Biotech’s Anti-Muscle-Wasting Combo Therapy Zepbound is an injectable prescription medicine that may help adults with obesity or some ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug. Kisunla (donanemab) is the second in a new generation of ...

Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

While many other American companies navigated various hurdles in the first quarter, there was nothing to slow the roll of Eli Lilly ... including Japanese companies Daiichi Sankyo (+21%) and ...

NEW YORK (AP) — U.S. stocks are nudging lower on Tuesday, and oil prices are rising again. It’s a modest return to form for ...

U.S. stocks are falling and oil prices are rising again. The S&P 500 fell 0.8% Tuesday. The Dow Jones Industrial Average lost ...